Stay updated with breaking news from Nasdaq Srpt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target dropped by equities researchers at Needham & Company LLC from $185.00 to $82.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s target price indicates a potential upside of […]
Mackenzie Financial Corp cut its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 19.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,847 shares of the biotechnology company’s stock after selling 7,935 shares during the period. Mackenzie Financial Corp’s holdings […]
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) reached a new 52-week low during trading on Tuesday after Oppenheimer downgraded the stock from an outperform rating to a market perform rating. The company traded as low as $55.25 and last traded at $61.24, with a volume of 8146682 shares. The stock had previously […]
Hhlr Advisors LTD. purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,404 shares of the biotechnology company’s stock, valued at approximately $1,434,000. A number of other institutional investors […]
Boxer Capital LLC purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 775,000 shares of the biotechnology company’s stock, valued at approximately $106,818,000. Sarepta Therapeutics accounts for approximately […]